BriaCell Therapeutics Completes Share Consolidation

Philadelphia and Vancouver – January 27, 2025

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company focusing on developing novel immunotherapies for cancer treatment, announced on January 24, 2025, that they have completed a share consolidation. The consolidation involved combining every fifteen pre-consolidation common shares into one post-consolidation common share. The goal of this consolidation is to ensure compliance with The Nasdaq Capital Market’s listing requirements.

Impact on Individuals:

For individual investors in BriaCell Therapeutics, the share consolidation may lead to a higher share price for each post-consolidation common share. This can impact the overall value of an investor’s holdings in the company. It’s essential for investors to stay informed about these changes and consult with financial advisors if necessary to understand the implications.

Impact on the World:

The completion of the share consolidation by BriaCell Therapeutics highlights the company’s commitment to maintaining compliance with market listing requirements. This move can enhance the company’s credibility and reputation in the biotechnology sector, potentially attracting more investors and partners. Ultimately, the development of novel immunotherapies for cancer care could have a positive impact on global healthcare by offering new and improved treatment options for patients worldwide.

Conclusion:

In conclusion, BriaCell Therapeutics’ share consolidation is a strategic decision aimed at ensuring regulatory compliance and advancing the development of innovative cancer therapies. Individual investors should monitor the impact on their holdings, while the global community looks forward to the potential benefits of enhanced cancer care options in the future.